UBS raised the firm’s price target on Edwards Lifesciences to $95 from $92 and keeps a Neutral rating on the shares. Edwards’s Q1 results were slightly above expectations with 10% constant currency sales growth, and UBS came away from the call with little to shake its confidence in the company’s ability to achieve its current 8%-10% global Transcatheter Aortic Valve Replacement sales growth guidance, the analyst tells investors in a research note. UBS views this quarter as supportive of the view that Edwards can sustain a high single digit/low double digit sales growth rate, but the firm is still searching for conviction in upside to this target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- EW Upcoming Earnings Report: What to Expect?
- Edwards Lifesciences price target raised to $101 from $95 at RBC Capital
- Edwards Lifesciences price target raised to $105 from $95 at Mizuho
- SMART data a ‘modest win’ for Medtronic, says Jefferies
- Edwards Lifesciences price target raised to $98 from $90 at Citi